Cboe Canada Inc. has granted final approval for the listing of transferable depositary receipts (Canadian depositary receipts or CDRs) to be issued in one or more series, as described in Bank of Montreal's short form base shelf prospectus dated Jan. 27, 2025. Each series of CDRs relates to a single class of equity securities of an issuer incorporated or formed under the laws of a jurisdiction outside of Canada.

Pursuant to issuer supplements dated Jan. 27, 2025, and Jan. 30, 2025, to the prospectus supplements dated Jan. 27, 2025, and Jan. 30, 2025, and to the base shelf prospectus, series of CDRs for the underlying issuers will be listed, as shown in the attached table.

Subject to confirmation of closing, the series of CDRs for the underlying issuers will be listed and available for trading on Cboe Canada at the start of trading on Thursday, Feb. 20, 2025.

The series of CDRs for the underlying issuers will settle on a standard T-plus-one settlement cycle.

Additional information about the CDRs and the underlying issuers may be found in the base shelf prospectus, and applicable issuer supplement and jurisdiction supplement, each of which is available on SEDAR+.

Security and trading information

Security name:  Novo Nordisk CDR (CAD Hedged)

Symbol:  NVON

Security type:  depositary receipt

Cusip No.:  67010H 10 9

ISIN:  CA 67010H 10 9 1

Units issued:  120,000

Price:  $9.54

Listing date:  Feb. 20, 2025

Trading currency:  Canadian dollar

Settlement cycle:  T plus one

Designated market-maker:  BMO Nesbitt Burns

Transfer agent and registrar:  TSX Trust Company